Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios pisa, s.a. de c.v. - mitomicina - mitomicina....5 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft fur klinische spezialpraparate mbh - mitomycin - pdr+solv/soln/intravesical use - 20 milligram(s) - other cytotoxic antibiotics; mitomycin

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Ireland - English - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - mitomycin - powder and solvent for intravesical solution - 40 milligram(s) - other cytotoxic antibiotics; mitomycin

United States - English - NLM (National Library of Medicine)

accord healthcare inc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin 40 mg in 80 ml - mitomycin for injection is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes. insufficient data from clinical studies of mitomycin are available for patients 65 years of age and older to determine whether they respond differently than younger patients. postmarketing surveillance suggests that elderly patients may be more susceptible than younger patients to injection site reactions (see adverse reactions: integument and mucous mem

United States - English - NLM (National Library of Medicine)

mylan institutional llc - mitomycin (unii: 50sg953sk6) (mitomycin - unii:50sg953sk6) - mitomycin 40 mg in 80 ml - mitomycin for injection, usp is not recommended as single-agent, primary therapy. it has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: mannitol - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.